Chemical Compound Review:
Biotecan
Synonyms:
Camptosar, irinotecan, Irinotecanum, Irinotecan Hcl, CHEMBL481, ...
David D. Lawrence,
Shogo Ozawa,
Noboru Yamamoto,
Kuniaki Shirao,
Mayumi Saeki,
Yasuhide Yamada,
Jennifer Marcello,
Farukh A. Durrani,
James E. Herndon,
Shousong Cao,
Patrick F. Smith,
Annick Desjardins,
John Sampson,
Tetsuya Hamaguchi,
Jennifer A. Quinn,
Darell D. Bigner,
Allan H. Friedman,
Henry S. Friedman,
Hironobu Ohmatsu,
Nagahiro Saijo,
David A. Reardon,
Leighann Bailey,
Henry S. Friedman,
Atsushi Ohtsu,
Teruhiko Yoshida,
Nahoko Kaniwa,
Annick Desjardins,
Hironobu Minami,
Kaoru Kubota,
Youcef M. Rustum,
Yoshiro Saito,
Renuka V. Iyer,
Kazuhiro Suzuki,
Patrick J. Creaven,
Milind M. Javle,
Sridharan Gururangan,
Sith Sathornsumetee,
Kimie Sai,
Jun-ichi Sawada,
James J. Vredenburgh,
Diane C. Noel,
David A. Reardon,
Lakshmi Pendyala,
James J. Vredenburgh,
Jeremy N. Rich,
- Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J., Hamaguchi, T., Yamamoto, N., Shirao, K., Yamada, Y., Ohmatsu, H., Kubota, K., Yoshida, T., Ohtsu, A., Saijo, N. Pharmacogenet. Genomics (2007)
- Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Hoskins, J.M., Marcuello, E., Altes, A., Marsh, S., Maxwell, T., Van Booven, D.J., Paré, L., Culverhouse, R., McLeod, H.L., Baiget, M. Clin. Cancer Res. (2008)
- Clinical determinants of response to irinotecan-based therapy derived from cell line models. Allen, W.L., Coyle, V.M., Jithesh, P.V., Proutski, I., Stevenson, L., Fenning, C., Longley, D.B., Wilson, R.H., Gordon, M., Lenz, H.J., Johnston, P.G. Clin. Cancer Res. (2008)
- Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Desjardins, A., Reardon, D.A., Herndon, J.E., Marcello, J., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., Bigner, D.D., Friedman, A.H., Friedman, H.S., Vredenburgh, J.J. Clin. Cancer Res. (2008)
- Experience with irinotecan for the treatment of malignant glioma. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Friedman, H.S. Neuro-oncology (2009)
- Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Loghin, M.E., Prados, M.D., Wen, P., Junck, L., Lieberman, F., Fine, H., Fink, K.L., Metha, M., Kuhn, J., Lamborn, K., Chang, S.M., Cloughesy, T., DeAngelis, L.M., Robins, I.H., Aldape, K.D., Yung, W.K. Clin. Cancer Res. (2007)
- Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Javle, M.M., Cao, S., Durrani, F.A., Pendyala, L., Lawrence, D.D., Smith, P.F., Creaven, P.J., Noel, D.C., Iyer, R.V., Rustum, Y.M. Clin. Cancer Res. (2007)
- A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. van der Bol, J.M., Mathijssen, R.H., Creemers, G.J., Planting, A.S., Loos, W.J., Wiemer, E.A., Friberg, L.E., Verweij, J., Sparreboom, A., de Jong, F.A. Clin. Cancer Res. (2010)